

Supporting Information

Tassi et al. 10.1073/pnas.1000779107

Table S1. Clinical characteristics and ongoing treatment of CAPS patients

Patient	Sex	<i>CIAS-1</i> mutation	Disease onset	Age, years	Therapy
C1	M	N477K	Birth	10.75	Anakinra 1 mg/kg/day
C2	F	D303N	1 week	9.2	Canakinumab 2 mg/kg
C3	M	T348M	6 months	23.2	—
C4	M	I572F	2 weeks	12.2	—
C5	F	—	Birth	15.7	—
MW1	M	R260W	2 years	13	—
MW2	F	R260W	6 years	43	—
MW3	F	D303N	3 weeks	3.5	Anakinra 1 mg/kg/day
MW4	F	E525K	15 months	15.6	—

Table S2. Clinical characteristics and ongoing treatment of SoJIA patients

Patient	Sex	Disease onset, years	Age, years	Steroid treatment	Other treatment
JIA1	F	9.8	9.8	Prednisone 1.5 mg/kg/day	—
JIA2	M	12.3	15.9	Prednisone 0.2 mg/kg/day	NSAID
JIA3	F	0.9	4.5	Prednisone 0.7 mg/kg/day	Thalidomide, abatacept
JIA4	F	3.2	11	—	NSAID
JIA5	M	7.2	9.9	Prednisone 0.3 mg/kg/day	NSAID

NSAID, nonsteroidal antiinflammatory drug.